A J Armstrong1, P Lin2, C S Higano3, C N Sternberg4, G Sonpavde5, B Tombal6, A J Templeton7, K Fizazi8, D Phung9, E K Wong2, A Krivoshik10, T M Beer11. 1. Division of Medical Oncology and Urology, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute Duke University, Durham. Electronic address: andrew.armstrong@duke.edu. 2. Biostatistics (Lin) and Medical Affairs (Wong), Pfizer Inc, San Francisco. 3. Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA. 4. Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. 5. Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, USA. 6. Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium. 7. Department of Oncology, St. Claraspital and University of Basel, Basel, Switzerland. 8. Department of Cancer Medicine, Institut Gustave Roussy University of Paris Sud, Villejuif, France. 9. Biostatistics, Astellas Pharma Europe BV, Leiden, The Netherlands. 10. Medical Sciences, Astellas Pharma US, Inc, Northbrook. 11. Hematology/Medical Oncology, OHSU Knight Cancer Institute Oregon Health & Science University, Portland, USA.
Abstract
Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated withenzalutamide. Patients and methods: Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results: Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR-NYR), 34.2 months (31.5-NYR), and 21.1 months (17.5-25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14-0.29) and 0.40 (0.30-0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions: Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated withenzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration: ClinicalTrials.gov: NCT01212991.
RCT Entities:
Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated with enzalutamide. Patients and methods: Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results:Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR-NYR), 34.2 months (31.5-NYR), and 21.1 months (17.5-25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14-0.29) and 0.40 (0.30-0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions: Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration: ClinicalTrials.gov: NCT01212991.
Authors: Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin Journal: Eur Urol Date: 2017-06-24 Impact factor: 20.096
Authors: Charles J Ryan; Thian Kheoh; Jinhui Li; Arturo Molina; Peter De Porre; Joan Carles; Eleni Efstathiou; Philip W Kantoff; Peter F A Mulders; Fred Saad; Kim N Chi Journal: Clin Genitourin Cancer Date: 2017-07-25 Impact factor: 2.872
Authors: Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono Journal: Lancet Oncol Date: 2012-09-18 Impact factor: 41.316
Authors: Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor Journal: N Engl J Med Date: 2013-07-18 Impact factor: 91.245
Authors: Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: K N Chi; T Kheoh; C J Ryan; A Molina; J Bellmunt; N J Vogelzang; D E Rathkopf; K Fizazi; P W Kantoff; J Li; A A Azad; B J Eigl; D Y C Heng; A M Joshua; J S de Bono; H I Scher Journal: Ann Oncol Date: 2015-12-18 Impact factor: 32.976
Authors: Andrew J Armstrong; Fred Saad; Carl Dmuchowski; Neal D Shore; Karim Fizazi; Mohammad Hirmand; David Forer; Howard I Scher; Johann De Bono Journal: Cancer Date: 2017-02-07 Impact factor: 6.860
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Anuradha Jayaram; Anna Wingate; Daniel Wetterskog; Vincenza Conteduca; Daniel Khalaf; Mansour Taghavi Azar Sharabiani; Fabio Calabrò; Lorraine Barwell; Susan Feyerabend; Enrique Grande; Alberto Martinez-Carrasco; Albert Font; Alfredo Berruti; Cora N Sternberg; Rob Jones; Florence Lefresne; Marjolein Lahaye; Shibu Thomas; Shilpy Joshi; Dong Shen; Deborah Ricci; Michael Gormley; Axel S Merseburger; Bertrand Tombal; Matti Annala; Kim N Chi; Ugo De Giorgi; Enrique Gonzalez-Billalabeitia; Alexander W Wyatt; Gerhardt Attard Journal: JCO Precis Oncol Date: 2019-09-24
Authors: Juan José Serrano Domingo; Teresa Alonso Gordoa; Javier Lorca Álvaro; Javier Molina-Cerrillo; Arantzazu Barquín García; Olga Martínez Sáez; Javier Burgos Revilla; Alfredo Carrato; Sara Álvarez Rodríguez Journal: Ther Adv Urol Date: 2021-09-17
Authors: Daniel J George; Neeraj Agarwal; Oliver Sartor; Cora N Sternberg; Bertrand Tombal; Fred Saad; Kurt Miller; Niculae Constantinovici; Helen Guo; John Reeves; XiaoLong Jiao; Per Sandström; Frank Verholen; Celestia S Higano; Neal Shore Journal: Prostate Cancer Prostatic Dis Date: 2022-02-21 Impact factor: 5.455
Authors: Lawrence Fong; Michael J Morris; Andrew J Armstrong; Daniel P Petrylak; Oliver Sartor; Celestia S Higano; Lance Pagliaro; Ajjai Alva; Leonard J Appleman; Winston Tan; Ulka Vaishampayan; Raphaelle Porcu; Darren Tayama; Edward E Kadel; Kobe C Yuen; Asim Datye Journal: Clin Cancer Res Date: 2021-06-09 Impact factor: 13.801
Authors: Jamie M Sperger; Hamid Emamekhoo; Rana R McKay; Charlotte N Stahlfeld; Anupama Singh; Xinyi E Chen; Lucia Kwak; Cole S Gilsdorf; Serena K Wolfe; Xiao X Wei; Rebecca Silver; Zhenwei Zhang; Michael J Morris; Glenn Bubley; Felix Y Feng; Howard I Scher; Dana Rathkopf; Scott M Dehm; Toni K Choueiri; Susan Halabi; Andrew J Armstrong; Alexander W Wyatt; Mary-Ellen Taplin; Shuang G Zhao; Joshua M Lang Journal: J Clin Oncol Date: 2021-07-01 Impact factor: 50.717
Authors: Emmy Boerrigter; Guillemette E Benoist; Inge M van Oort; Gerald W Verhaegh; Anton F J de Haan; Onno van Hooij; Levi Groen; Frank Smit; Irma M Oving; Pieter de Mol; Tineke J Smilde; Diederik M Somford; Paul Hamberg; Vincent O Dezentjé; Niven Mehra; Nielka P van Erp; Jack A Schalken Journal: Cancers (Basel) Date: 2021-12-14 Impact factor: 6.639